DASA-58 is a potent, selective, and cell-active inhibitor of SRPK1 (serine/arginine-rich protein kinase 1), a key enzyme in alternative pre-mRNA splicing regulation. It is primarily utilized in chemical biology and drug discovery as a chemical probe to study SRPK1 function in cancer and other diseases driven by splicing dysregulation. DASA-58 inhibits SRPK1-mediated phosphorylation of splicing factors such as SRSF1, altering splice site selection and providing insights into therapeutic targeting of splicing kinases. Researchers employ it in cellular studies and preclinical models to assess efficacy, specificity, and potential for novel splicing-targeted therapies, advancing medicinal chemistry and pharmacology.